|
|
Acambis PLC - Comparative Business Analysis Snapshot
Business Description
Acambis PLC. The Group's principal activity is researching, developing and manufacturing vaccines to prevent and treat infectious diseases. The Group's vaccine product are ChimeriVax-JE and ChimeriVax-West Nile. ChimeriVax-JE is a single-dose vaccine for travellers and those living in endemic regions. ChimeriVax-West Nile focuses on viruses transmitted to humans and animals by the bite of an infected mosquito. The Group's other pipeline products are Clostridium difficile and Influenza vaccine. The Group operates in the United Kingdom and the United States of America.
Competitor Analysis
This analysis compares Acambis PLC with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
